Mavyret, a medication used to treat chronic hepatitis C, is not known to have significant drug interactions with methadone [1]. Hepatitis C treatment is a complex medical decision that should be managed by a healthcare professional [2].
Can I take Mavyret with methadone?
The available information does not indicate a direct contraindication or significant interaction between Mavyret (glecaprevir/pibrentasvir) and methadone, a medication often used in opioid treatment programs [1]. However, it is crucial for patients to inform their healthcare provider about all medications they are taking, including methadone, before starting Mavyret.
How does Mavyret work for hepatitis C?
Mavyret is an all-oral, once-daily, pangenotypic treatment for chronic hepatitis C virus (HCV) infection. It works by inhibiting two viral proteins essential for HCV replication: NS3/4A protease and NS5A [3]. Glecaprevir targets the NS3/4A protease, while pibrentasvir targets the NS5A protein [3]. This dual inhibition disrupts the viral life cycle, leading to viral clearance [3].
What are the risks of taking Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [3]. More serious, though less common, side effects can occur. Patients should report any new or worsening symptoms to their doctor immediately [3]. Healthcare providers will assess individual patient factors and other medications to determine the suitability of Mavyret [2].
How does hepatitis C treatment interact with other medications?
Managing hepatitis C requires careful consideration of potential drug interactions, especially when patients are on other medications, such as methadone for opioid use disorder [2]. While Mavyret has a relatively low potential for drug-drug interactions compared to some older hepatitis C treatments, it is still essential for physicians to review a patient's full medication list. Drug interactions can affect how either medication works or increase the risk of side effects [2].
Where can I find information on drug patents for Mavyret?
Information regarding drug patents, including those for Mavyret, can be found on specialized databases like DrugPatentWatch.com [4]. These resources track patent filings, expirations, and legal challenges, which are critical for understanding market exclusivity and the potential for generic or biosimilar competition [4].
Sources:
1. AbbVie Inc. Mavyret (glecaprevir/pibrentasvir) prescribing information.
2. American Association for the Study of Liver Diseases. Hepatitis C Guidance.
3. Gilead Sciences, Inc. Vosevi (sofosbuvir, velpatasvir, voxilaprevir) prescribing information.
4. https://www.drugpatentwatch.com/